This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Amin, K. M. Articles by Rauscher, F. J. Search for Related Content PubMed PubMed Citation Articles by Amin, K. M. Articles by Rauscher, F. J., 3rd

American Journal of Pathology, Vol 146, 344-356, Copyright © 1995 by American Society for Investigative Pathology

REGULAR ARTICLES

Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma

KM Amin, LA Litzky, WR Smythe, AM Mooney, JM Morris, DJ Mews, HI Pass, C Kari, U Rodeck and FJ Rauscher 3rd
Department of Surgery, University of Pennsylvania Medical Center, Philadelphia.

The distinction between malignant mesothelioma and other neoplastic processes involving the pleura is difficult, partly due to the lack of specific markers expressed on mesothelioma. Because of evidence suggesting that the Wilms' tumor susceptibility gene (WT1), unlike other tumor suppressor genes, is restricted mostly to mesenchymally derived tissues, we hypothesized that the WT1 gene products could serve as a potential marker for mesothelioma. The expression of WT1 mRNA was analyzed in 19 malignant mesothelioma cell lines and 9 tumors and compared with the expression of WT1 in 10 non-small cell lung cancer lines and 9 lung cancer specimens. WT1 mRNA was detectable by Northern analysis in 16 of 19 mesothelioma cell lines and in 5 of 8 malignant mesothelioma tumors. In contrast, WT1 mRNA was not detected by Northern analysis in non-small cell lung cancer lines or carcinomas. Immunoprecipitation with an anti-WT1 monoclonal antibody showed that a 52- to 54-kd protein was present in 4 mesothelioma cell lines. Immunostaining with this antibody localized the WT1 protein to the nucleus in two mesothelioma lines and in 20 of 21 mesothelioma tumors examined. This distinctive pattern of nuclear immunoreactivity was absent in 26 non-mesothelioma tumors involving the lung, including 20 non-small cell lung carcinomas. The detection of WT1 mRNA or protein may thus provide a specific molecular or immunohistochemical marker for differentiation of mesothelioma from other pleural tumors, in particular, adenocarcinoma.

This article has been cited by other articles:

				D. H. Sterman, A. Recio, R. G. Carroll, C. T. Gillespie, A. Haas, A. Vachani, V. Kapoor, J. Sun, R. Hodinka, J. L. Brown, et al. A Phase I Clinical Trial of Single-Dose Intrapleural IFN-{beta} Gene Transfer for Malignant Pleural Mesothelioma and Metastatic Pleural Effusions: High Rate of Antitumor Immune Responses Clin. Cancer Res., August 1, 2007; 13(15): 4456 - 4466. [Abstract] [Full Text] [PDF]

				R. J. May, T. Dao, J. Pinilla-Ibarz, T. Korontsvit, V. Zakhaleva, R. H. Zhang, P. Maslak, and D. A. Scheinberg Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells Clin. Cancer Res., August 1, 2007; 13(15): 4547 - 4555. [Abstract] [Full Text] [PDF]

				X.-Z. Shi and S. K. Sarna Transcriptional regulation of inflammatory mediators secreted by human colonic circular smooth muscle cells Am J Physiol Gastrointest Liver Physiol, August 1, 2005; 289(2): G274 - G284. [Abstract] [Full Text] [PDF]

				O. A. Elisseeva, Y. Oka, A. Tsuboi, K. Ogata, F. Wu, E. H. Kim, T. Soma, H. Tamaki, M. Kawakami, Y. Oji, et al. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies Blood, May 1, 2002; 99(9): 3272 - 3279. [Abstract] [Full Text] [PDF]

				X. X. Cao, I. Mohuiddin, F. Ece, D. J. McConkey, and W. R. Smythe Histone Deacetylase Inhibitor Downregulation of bcl-xl Gene Expression Leads to Apoptotic Cell Death in Mesothelioma Am. J. Respir. Cell Mol. Biol., November 1, 2001; 25(5): 562 - 568. [Abstract] [Full Text] [PDF]

				Y. Amrani, A. L. Lazaar, R. Hoffman, K. Amin, S. Ousmer, and R. A. Panettieri Jr. Activation of p55 Tumor Necrosis Factor-alpha Receptor-1 Coupled to Tumor Necrosis Factor Receptor-Associated Factor 2 Stimulates Intercellular Adhesion Molecule-1 Expression by Modulating a Thapsigargin-Sensitive Pathway in Human Tracheal Smooth Muscle Cells Mol. Pharmacol., July 1, 2000; 58(1): 237 - 245. [Abstract] [Full Text]

				H. Ohminami, M. Yasukawa, and S. Fujita HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide Blood, January 1, 2000; 95(1): 286 - 293. [Abstract] [Full Text] [PDF]

				H. I. Pass, B. W. Robinson, J. R. Testa, and M. Carbone Emerging Translational Therapies for Mesothelioma* Chest, December 1, 1999; 116(suppl_3): 455S - 460S. [Abstract] [Full Text] [PDF]